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ABSTRACT 
The in vivo lipid mobilizing effect of alpha9 adrenergic antagonist 
has been demonstrated previously. This has attracted attention 
to the putative interest of such compounds in a lipid-mobilizing 
strategy. RP 55462 [6chlor~isopropylmino)5~methyl)2 pi- 
perazinopyrimidine], a piperazinopyrimidine derivative, has al- 
ready been shown to exert elpha-2 adrenergic antagonist actions 
on fat cell function in vitro. Moreover, RP 55462 exhibits a direct 
in vitro lipolyt~~ action w h i i  is independent of its alpha-2- 
blocking potency. When administered i.v. RP 55462 is also able 
to induce an increment in plasma nonesterified levels in dogs. 
The mechanism of action of RP 55462 was studied and the 
nature of its lipomobtlizing effect was exdored. RP 55642- 
dependent lipdysis was not affected by beta adrenergic blockers 
on rat fat cells and RP 55462 had no direct effect on adenylyl- 
cydase activity on fat cell membranes. Moreover, RP 55462 did 
not compete with Wlphenyl isopropyl adenosine binding (Al- 
adenosine receptor agonist) on fat cell membranes. In fact, RP 
55462 inhibited, in a -t manner, the cyclic AMP 
(cAMP)dependent phosphodiiterase (PDE) activity in rat adi- 
pose tissue. Several derivatives with the piperazinopyrimidine 
structure also inhibited CAMPdepeMent PDE activity and ex- 
erted li- effects. A short structure-activity study was per- 
f m e d  with various derivatives. In dogs, by contrast with yohim- 
bine, the in vivo lipid mobilizing effect of RP 55462 was not 
abolished by pretreatment with propramlol, and lasted longer. It 
is conduded that the in vivo lipolytic activity of RP 55462 is 
connected with its ability to inhibit cAMPdeper&nt PDE activity; 
a property of several piperazinopyrimidine derivatives. The lipid 
mobilizing effect induced in vivo by RP 55462 results from a 
combination of its alpha-2 adrenergic antagonist properties and 
its direct lipolybc action mediated by CAMP-dependent PDE 
inhibiting effects. 
Recent investigations in our laboratory have demonstrated 
the lipid mobilizing effect of an alpha-2 adrenergic antagonist 
(yohimbine) which suggested a putative interest of such com- 
pounds in lipid mobilizing strategies. Oral administration of 
yohimbine to fasting human subjects promotes an increase in 
plasma NEFA and glycerol levels. This action can be prevented 
by a meal or by the administration of a beta-antagonist like 
propranolol before yohimbine intake (Galitzky et d, 1988; 
Taouis et d, 1988). This effect is attributable to: 1) an increase 
in synaptic norepinephrine (due to an increment of the ortho- 
sympathetic tone through central and/or peripheral effects) 
with a resultant rise in beta adrenergic-dependent lipolysis and 
2) a blockade of the antilipolytic post junctional alpha-2 adre- 
noceptors of the adipocyte. 
In the course of our search for new alpha-2 adrenergic antag- 
onists, we studied a new agent, RP 55462 [6-chloro-4-(isopro- 
py1amino)-5-(methyl)-2 piperazino- pyrimidine] which repre- 
sents a new chemical family of alpha-2 adrenergic antagonists 
(Gueremy et d, 1986). We fmt confirmed the alpha-2 adrener- 
gic antagonist properties of RP 55462 on white fat cells by 
functional (inhibition of the alpha-2 adrenergic-dependent an- 
tilipolysis) and binding studies (competition with [aH]yohim- 
bine binding on alpha-2 adrenoceptors on human fat cell mem- 
branes). We also demonstrated that RP 55462 was able to 
promote an increment of the plasma NEFA levels after i.v. 
injection in dogs, an effect which could be attributable to its 
alpha-2-blockingpotencies. However, we noticed that RP 55462 
was able to activate lipolysis in vivo on isolated fat cells from 
different species. This effect, which had never been described 
Received for publication February 22. 1989. 
'A part of theae mulb have been published under Abstract form at the 1st with other alpha-2 adrenergic antagonists, like yohimbine, id- 
h p e r n  Con- on Obesity held in Stockholm (Sweden), June 6-6,1988. azoxan and phentolamine, is apparently linked to a specific 
-- 
ABBREVIATIONS: NEFA, nonesterified acids; CAMP, cyclic AMP; PDE, phosphodiesterase; KRBA, Krebs-Ringer bicarbonate albumin buffer; EGTA, 
ethylene glycol bis(g9mimyl ether)-N,N'-tetraacetic add; PIA, phenyl isoprod adenosine; ADA, adenosine deaminase; IBIWOC isobutyl methyl 
xanthine. 
Vol. 251 
mechanism of action which is independent from the alpha-2- 
blocking properties of the agent (Saulnier-Blache et aL, 1989). 
The present study is focused on the clarification of the effects 
of RP 55462. This compound seems to be a good candidate for 
use in antiobesity therapy through lipomobilization with a 
combination of alpha-2 adrenolytic action and direct lipolytic 
activity. The study was conducted in order to determine the in 
uitm lipolytic mechanism of action of RP 55462 and to delineate 
the contribution of a direct (not alpha-2 adrenergic dependent) 
lipolytic action in the lipid mobilizing effect of RP 55462 in 
oiuo. 
A large part of the lipolysis studies were carried out on the 
fat cells of the rat in order to exclude possible interactions of 
RP 55462 with alpha-2 adrenoceptors in as much as rat fat 
cells are characterized by a small number of functional alpha- 
2 adrenoceptors (C-nB et aL, 1983) and a weak alpha-2 
adrenergic responsiveness (Rebourcet et al., 1988). 
We demonstrated that the in uitro lipolytic activity of RP 
55462 is mediated by inhibition of CAMP-dependent PDE 
activity. Moreover, the in uiuo lipid mobilizing effect of RP 
55462 is the result of a combination of its alpha-2 adrenergic 
properties and its direct lipolytic action. 
Methods 
Animals. Male Sprague-Dawley rats weighing between 250 and 350 
g and male golden hamsters (Mesocricetus aumtus) weighing between 
100 and 145 g, were housed at  20-22'C and were fed ad libitum before 
use. They were sacrificed by decapitation after an overnight fast. 
Epididymal and perirenal adipose tissue were removed immediately 
and used for biological assays. 
Fat cell preparation. Isolated adipocytes were obtained from adi- 
pose tissue according to Rodbell's method (1964) with minor modifi- 
cations. The tissue was cut into small pieces and incubated for 30 to 
40 min at  37'C under vigorous agitation in KRBA, pH 7.5, with 35 mg/ 
ml of bovine serum albumin and 6 mM glucose (KRBA buffer) con- 
taining 1.6 mg/ml of collagenase. After incubation the cells were filtered 
through a silk screen (250 pm mesh) and washed twice with the KRBA 
buffer in order to eliminate the s t r o m a - v d  fraction and the 
collagenase. 
Lipolysir meaaurementa. Isolated adipocytes (20-30 mg of total 
lipid) were dispersed in 1 ml of KRBA buffer containing 10 pl of various 
concentrations of RP 55462 or the other agonists tested. After 90 min 
of incubation under gentle agitation at  37'C the reaction was stopped 
in ice and an (200 pl) aliquot of the incubation medium was taken to 
determine the glycerol released by the cells according to Wieland's 
method (1957). The lipid content of the incubation vials was deter- 
mined gravimetrically after extraction according to the method of Dole 
and Meinertz (1960). Results are expressed in moles of glycerol released 
per 100 mg of total cell lipid. 
Preparation of adipocyte membranes. Crude membranee were 
obtained after hypotonic ly i s  of the adipocytes. The lysing medium 
was composed of 2.5 mM MgCl,, 1 mM KHCOS, 2 mM Tris-HC1, 100 
pM EGTA (pH 7.5; 35 mOsmol) and the following protease inhibitors: 
leupeptin (1 pg/ml), benzamidine (0.1 mM) and 100 pM phenylmethyl 
sulfonyl fluoride. For adenylyl-cyclaee assays the lysing medium was 
complemented with 0.2 mM ATP. The lysis of adipocyte suspeneions 
was performed at  20-22% in order to minimize trapping of membranes 
in the coaleecing fat cake. Fat cell ghosta were obtained by centrifuga- 
tion (40,000 X g, 10 rnin at 15'C). The pellet was washed and resus- 
pended in 1 ml of lysing medium and frozen immediately at  -8VC 
until use in binding studies or adenylyl-cyclase assays. 
Radioligand binding rrtadiecl. Hamster fat cell Al-adenosine re- 
ceptors were identified with [WIPIA. Thawed crude membranes were 
washed once in 50 mM Trie-HC1 and 1 mM EDTA, pH 7.5, and then 
in 50 mM Tris HCI and 10 mM MgCI*, pH 7.5, and finally resuspended 
in this medium containing 1 pg/ml of ADA. Incubation buffer consisted 
in 100 pl of aqueous radioligand solution (10 nM) and 100 pl of 
membrane suspension (100-200 pg of protein) made up to a final 
volume of 400 pl with 50 mM Tris HCl, 10 mM MgCl, and 1 pg/ml of 
ADA, pH 7.5. RP 55462 or other competing agents were added to the 
assay mixture at  various concentrations ranging from lo4 to M. 
Incubations were carried out a t  37'C in a water bath for 30 min under 
constant shaking. At the end of the incubation, the mixture was diluted 
with 4 ml of ice-cold buffer and vacuum filtered immediately through 
Whatman GF/C glass fiber filters faced on a Millipore manifold. The 
filters were washed twice with 10 ml of ice-cold buffer and counted in 
4 ml of scintillation medium in a Packard scintillation spectrometer a t  
an efficiency of 45%. Residual binding was expressed as percentage of 
total ['HIPIA binding (100% biding was defined in the absence of 
competitors). Protein content was measured by the method of Lowry 
et aL (1951) using bovine serum albumin as standard. 
Determination of the CAMP-dependent phosphodieeterase 
activity. The CAMP-PDE activity was assayed on white adipose tissue 
homogenah, according to the method described by De Mazancourt 
and Giudicelli (1984). Epididymal adipose tissue was removed from 
rats, washed twice in 75 mM Tris and 10 mM MgClz, pH 7.4, buffer. 
The tissue was homogenized in a Potter apparatus in 10 ml of buffer 
and centrifuged 5 min at  3000 rpm at  4'C. The CAMP-PDE activity 
was determined in the liquid phase; 60 to 90 pg of protein were 
incubated at  37'C for 10 min in a final volume of 250 pl containing 
0.62 pM CAMP, 2.4 nM ['HICAMP, 5 mM MgCl,, 0.04% bovine serum 
albumin and 30 mM Tris-HC1, pH 7.4. A warm denaturized homogenate 
(2 min at 90'C) was used as blank. The reaction was stopped by 
addition of 200 pl of 0.24 M Ba(OH), and 200 pl of 0.24 M ZnSO,. 
After centrifugation for 10 min at  5000 x g, 200 pl of supernatant were 
counted in 4 ml of scintillation medium in a Packard scintillation 
spectrometer. All measurements were run in triplicate. After removing 
the blank value, CAMP-PDE activity was expressed in picomoles of the 
cAMP transformed per milligram of protein per minute. RP 55462 and 
other compounds were tested as inhibitors of basal CAMP-PDE activity. 
Adenylate-cyclase assays. Adenylate-cyclase assays were per- 
formed in duplicate in a final volume of 50 pl consisting of 10 pl of 
adipocyte membrane suspension (20-30 pg of protein), 20 pl of buffer 
or pharmacological agents at  a suitable concentration and 20 pl of 
concentrated incubation mixture containing the following agents to 
reach a final composition: 40 mM Tris-HC1, 2 mM Mg C12, 0.1 to 10 
pM GTP, 100 pM EGTA, 0.5 mM IBMX, 0.5 mM CAMP, 20 pM ATP, 
0.5 pCi of [ a q ] A T P ,  5 mM creatine phosphate, 0.2 mg/ml of creatine 
kinase, 0.2 mg/ml of bovine serum albumin and 2 &ml of ADA at  pH 
7.4. The reaction was initiated with 10 pl of thawed membranee washed 
once and then resuspended in 5 mM Tris-HC1 and 0.5 mM MgCI*; pH 
7.5, containing antiprotease compounds: leupeptin, 5 pl/ml; pepstatin, 
2 pg/ml; soybean trypsin inhibitor, 10 pglml; and 0.05 mM L-l-chloro- 
3- < 4-tosylamido > 4-phenyl-2-butanon. After a 20-min incubation at  
30°C the reaction was stopped by addition of 100 pl of a solution 
containing 2% lauryl sulfate, 40 mM ATP and 1.4 cAMP as well as 
trace amounta of [a-'HICAMP (7-8000 counts/min). [TICAMP was 
isolated by Dowex 50WX8 and neutral alumina chromatography as 
described previously (Salomon et al., 1974) with a 75 to 80 yield, and 
measured for radioactivity with a Packard liquid scintillation spectrom- 
eter. 
I n  vivo studies. Male Beagle dogs (15-20 kg) were used for the in 
vivo studies.A bolus injection of propranolol, RP 55462 or yohimbie 
were made at  time 10 min into the jugular vein, with the help of a 
catheter, in alert dogs. Blood samples were collected in heparhized 
tubes and centrifuged immediately. Plasma was collected and frozen at  
-20°C until utilization. Plasma NEFA levels were determined by a 
titrimetric method, after extraction, using the technique of Dole and 
Meinertz (1960). 
Chemicals. RP 55462 and its analogs defied in table 3 were kindly 
given by RhBne-Poulenc Sant.6 (Gennevilliers, France), (-)-N6-R-(G- 
['H])phenylisopropyl adenosine and (2,8-['HI) adenosine 3',5'-cyclic 
phosphate were obtained from Amersham International (Amersharn, 
England)., Propranolol and ICI-118551 were obtained from ICI Pharma 
(Alderly Park, England). Betaxolol was obtained from Synthelabo 
(Paris, France). Yohimbine hydrochloride, bovine serum albumin 
(Fraction V), IBMX, caffeine, forskolin, sodium fluoride, theophylline 
and (-)-epinephrine bitartrate were purchased from Sigma Chemical 
Co. (St. Louis, MO). Collagenaee (from Cbstridiurn histolyticurn at 0.4 
U/mg), ADA, (-)-PLA and enzymes for glycerol assays came from 
Boehringer Mannheim (Mannheim, FRG). All other chemicals and 
organic solvents were of reagent grade. 
Results 
In vitm Studies 
Comparison of the lipolytic activity of RP 55462 with other 
lipolytic agents. In order to determine the lipolytic efficiency 
of RP 55462 on rat fat cells, dose-effect curves were compared 
with those of different lipolytic agents like epinephrine, forsko- 
lin, IBMX and theophylline, the mechanism of action of which 
was well known. All the agents tested initiated a dose-depend- 
ent increase of the lipolytic activity with a decrease in the 
glycerol production at the highest doses (5 x lo-' M) for some 
agents: RP 55462, IBMX and theophylline (fig. 1). The ECw 
values and maximal effect values were determined for each 
lipolytic agent (table 1). The maximal lipolytic effect of RP 
55462 reached 70% of that induced by 0.1 pM isoproterenol. It 
was lower than the lipolytic action of epinephrine and forskolin 
but quite similar that of IBMX, theophylline and caffeine. The 
sensitivity of RP 55462 (ECso value) was lower than that of 
epinephrine or forskolin but quite equivalent to those of IBMX, 
theophylline and caffeine. All the comparative experiments 
Fig. 1. Comparison of the lipolytic activity of RP 55462 and of d i i e n t  
lipdytk agents on isolated rat fat cells. Isolated adipocytes were incu- 
bated in KRBA buffer with increasing concentrations of RP 55462 (A and 
BXA) (-)epinephrine (A,.), forskdin (A,O), IBMX (Bb) and theophylline 
(B,Q and caffeine (Bm. Glycerol release was measured as described 
under 'Materials and Methods.' The IipdVtic activity was expressed as 
a percentage of the effect initiated by 0.1 ;M isopm~erenoJ (6.23 * 0.62 
umd of ahmrol Der 100 ma of U d d l  after subtraction of the basal activitv 
(0.29 * 6.02 pm& of gly& p& 1 b O  rng of lipid). Each point represents 
the mean * S.E. of four separate experiments performed in duplite. 
TABLE 1 
SendtMty (E& values) and maximal effects of RP 55482 and 
different lipdytk agents on rat fat cells 
ECm values cud maximal stimulating effects were calculated from the hdhridual 
dcswffect curves depicted In Fi. 1 .  Results are mean * S.E. of 4 separate 
experiments. 
rM ~ g l v o e r c r l  100 nrO w 
Epinephrine 0.075 * 0.004 6.45 * 0.96 
Forskdin 0.44 * 0.06 5.81 * 0.99 
IBMX 11.2 f 1.5 5.11 + 0.47 
RP 55462 16.8 * 1.7 4.35 * 0.40 
Theophylline 39.8 * 3.2 4.1 4 * 0.43 
Caffeine 189.3 * 16.8 4.94 * 0.24 
Fig. 2. Influence of three beta adrenergic antagonists on the lipdytic 
activity of RP 55462 in rat fat cells. Isolated adipccytes were incubated 
in KRBA buffer containing 2 pglrnl of ADA with increasing concentram 
of RP 55462 in the absence (0) or presence of lo4 M propranold (A) 
1 O4 M betaxdol O or 1 0-6 M ICI 118551 (0). Glycerol release was 
determined as described under 'Materials and Methods.' Each point is 
the mean * S.E. of four separate experiments performed in duplite. 
described here were performed without removing adenosine 
from the incubation medium as some agents are known to act 
through an antagonization of A1 adenosine receptor sites. 
Determination of the in vitro lipolytic mechanism of 
action of RP 55462. Amongst the possible mechanisms of 
action of RP 55462, infraction with beta adrenoceptors or Al- 
adenosine receptor sites and direct impact on adenylate cyclase 
were tested. 
Interaction with beta adrenoceptors. The influence of 
three beta-blockers (propranolol, betaxolol and ICI-118551) was 
tested on the lipolytic dose-effect curve of RP 55462 on rat fat 
cells. Lipolytic assays were performed with 2 pg/ml ADA in the 
incubation buffer. Removal of adenosine promoted an incre- 
ment of basal lipolysis and greater sensitivity (shift to the left 
of the dose-response curve of RP 55462). As shown in figure 2, 
the dose-effect curve of RP 55462 was not modified either by 
higher concentrations of propranolol (mixed beta-1-beta-2 an- 
tagonist), betaxolol (beta-1-antagonist) or ICI 118551 (beta-2- 
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antagonist). Apparently, RP 55462 does not interact with rat 
fat cell beta adrenoceptors. 
Adenylyl-cyclase activity. The effect of increasing con- 
centrations of RP 55462 on adenylyl-cyclase activity of adipo- 
cyte membranes was compared with the stimulation obtained 
with agents known to activate this enzyme: isoproterenol, for- 
skolin and NaF. Whatever the concentration of RP 55462 used, 
(0.1 pM to 1 mM) basal adenylyl-cyclase activity (21 f 4 pmol 
of cAMP/mg of protein per 1 min) was never increased by this 
agent whereas isoproterenol (10 pM), forskolin (0.1 pM) and 
NaF (20 mM) induced an increase over basal activity of 138, 
97 and 533%, respectively. The absence of any direct interac- 
tion of RP 55462 with adenylyl-cyclase is demonstrated. 
Interaction with Al-adenosine receptors. The effect of 
RP 55462 on [3H]PIA (Al-adenosine agonist) binding was 
tested on hamster adipocyte membranes in as much as we had 
a good practice of [3H]PIA binding on the membranes and we 
obtained binding parameters which were more accurate than 
in the rat. [3H]PIA bound to hamster fat cell membranes with 
higher affinity and capacity &= 1.1 f 0.1 nM; maximal binding 
= 440 * 40 fmol/mg of protein). Competition of [3H]PIA 
binding with RP 55462 was compared with the competition 
obtained with PIA, theophylline and IBMX. 
As shown in figure 3, theophylline and IBMX inhibited [3H] 
PIA binding in a dose-dependent manner whereas RP 55462 
had no significant inhibitory effect. The inhibition of [3H]PIA 
binding by higher PIA concentrations was considered as defin- 
ing the nonspecific binding of the radioligand. The results 
suggested that RP 55462 does not have any interaction with 
Al-adenosine receptor sites. 
Inhibition of CAMP-dependent PDE activity. The effect 
of increasing concentrations of RP 55462 were tested on the 
basal CAMP-PDE activity of rat epididymal adipose tissue 
homogenates. 
As shown in figure 4, RP 55462 inhibited, in a dose-depend- 
ent manner, the basal CAMP-PDE activity. A significant effect 
was obtained with 1 pM RP 55462 leading to 10% inhibition of 
the basal activity. The maximal effect was observed with 1000 
pM leading to 95% inhibition of the basal activity; 50% of the 
maximal inhibition (ICm) was obtained at 40 pM RP 55462. 
A parallel was shown to exist between the lipolytic activity 
of 50 pM RP 55462, IBMX, theophylline and caffeine and the 
PI A THE0 IBMX RP55462 
-log (MI 
Fig. 3. Competition of [3H]PIA binding on hamster fat cell memkanes 
with RP 55462. PIA. IBMX and theophyWne (THEO). The membrane 
suspw&n was incubated with 10 nM w]PIA in the absence (100% 
totelbWhg)orhtheqesenoy,ofincreasingconcentra~ofPIA, 
IBMX and THEO. The residual binding was expressed as a percentage 
of the total w]PlA binding. Each column mpresmts the mean f S.E. of 
four separate experiments. 
z 
Bas. 0.1 1  1 0  5 0  1 0 0  1 0 0 0  
Fig. 4. Influence of RP 55462 on the basal (Bas) CAMP-PDE activity of 
rat epldidymal adipose tissue. T i  homogenates were incubated with 
increasing concentrations of RP 55462 and the residual Bas cAMPPDE 
activity was measured as described under 'Materials and Methods.' 
Each column represents the mean f S.E. of three separate experiments 
performed in triplicate. A Student's paired t test was used to estimate 
the significance of inhibition with regard to the Bas activity. *P < .05; 
**P < .02; M P  < .01. 
TABLE 2 
Comparison betW(HHI the lipdytic ettectr and the Inhibition of 
CAMP-WE aclivhy of RP 55462, IBMX, theophyllh and caffeine 
The same dose (50 pM) of each agent was used to deterrnkre the impact on the 
lipdytic activity in isdated fat cels incubeted ir KRBA buffer as described uder 
'Materiets and Methods' and the potencies to mbit the CAMP-PO€ activity h 
ep&!yW rat Ussue homogenates. Results are the meen of f u r  separate 
experments Performed h trip(icat8. Tl'm weakest Ypolytic egents afld 
caffeine) had the lowest WlibitClg effect on CAMPPDE actMty. 
IBMX 82 * 3 72 rt 2 
RP 55462 56 * 3 51 k 3  
Theophylline 41 f 10' 21 f 1' 
Caffeine 10 f 5' 16 f 1' 
P < 05; as wmpared with IBMX-Student's paired t test. 
capacity of the same concentration of these agents to inhibit 
the CAMP-PDE basal activity (table 2). The same order of 
potency was obtained with the two biological effects: IBMX > 
RP 55462 > theophylline > caffeine. 
Comparative study of differently substituted pipera- 
zinopyrimidine derivatives. A comparative study of the 
lipolytic effects and inhibiting action on the CAMP-PDE activ- 
ity of differently substituted piperazinopyrimidine derivatives 
was performed. This short study clearly revealed that substi- 
tution of the R1 group on piperazine nucleus by a methyl 
residue leads to agents which are inactive toward lipolysis and 
CAMP-PDE activity whatever the chemical nature of the R4, 
R3 and R2 moieties of the molecule (table 3). 
Moreover, when the group R1 was an hydrogen atom, changes 
in the chemical structure of substitutants R3 and R4 did not 
noticeably modify the CAMP-PDE inhibition potential or li- 
polytic activity of the different derivatives. 
In spite of the limited number of compounds available for 
this study, it is clear that there is a strict association between 
the lipolytic activity of some piperazinopyrimidine derivatives 
and their ability to inhibit CAMP-dependent PDE-activity. 
In Vivo Studies 
The influence of a preinjection (i.v.) of propranolol (beta 
adrenergic antagonist) on the lipomobilizing effect promoted 
by an i.v. injection of RP 55462 was compared with the influ- 
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TABLE 3 
R . k t k n  between the chemical rtructun, the CAMP-PDE inhibition capacity a d  the lipolytic activation of the soma dooe (50 f l)  of 
pipema- dNivauves 
The WJbltkn of CAMP- activity (n - 3) for each m m p x d  and the Gpolytk actMy (n = 6) are rounded off to the nearest percentage. Upolytic efficacy (expressed 
a s p ~ o f ~ ~ e f f e c t ~ t e d b y 0 . 1  rMisoproterend)wasdeRnedfmmCpolysis~perfomwdonintact~cels~tedhKRBAkrfferas 
desalmd under 'MatefUs and Memods.' 
R3 I 
ence on the lipomobilizing effect induced by yohirnbine. Exper- 
iments were carried out on alert dogs. As shown in figure 5, the 
increase in plasma NEFA levels induced by yohimbine was 
abolished completely under propranolol treatment whereas the 
increase in NEFA levels induced by RP 55462 was delayed in 
time but never abolished completely by propranolol pretreat- 
ment; a noticeable lipomobilizing action is still preserved after 
the administration of the beta-blocking agent. 
Discussion 
The in vivo lipid mobilizing action of alpha-2 adrenergic 
antagonists has already been demonstrated (Galitzky et d, 
1988, Taouis et d, 1988). We described previously that RP 
55462, representing a new family of alpha-2 adrenergic antag- 
onists, in addition to its alpha-2 adrenolytic potencies, was aleo 
able to activate the lipolysis of isolated fat cells from different 
species. This lipolytic activity was independent of its alpha-2 
adrenolytic properties (Saulnier-Blache et d, 1989). The aim 
of the present study was to determine the in uivo and in vitro 
lipolytic mechanism of action of RP 55462. It is demonstrated 
that this mechanism is associated to an inhibition of adipose 
tiesue CAMP-PDE activity. Moreover, the lipomobilizing effect 
promoted by RP 55462 administration results from both im- 
pacts ie .  its direct action on CAMP-PDE and its alpha-2 
antagonist effects. 
The in uitro lipolytic activity of RP 55462 was not modified 
by beta receptor blockade (propranolol, betaxolol or ICI 118551) 
(fig. 2). So the lipolytic activity of the drug is not mediated by 
the stimulation of a beta adrenergic receptor. 
RP 55462 was not able to directly stimulate adenylyl-cyclase 
activity on fat cell membranes, dismissing any direct or indirect 
interaction with the enzyme as is the case with some compounds 
(forskoline and NaF) which are able to stimulate lipolysis by 
direct activation of the adenylyl-cyclase complex without inter- 
action with specific receptors. 
The lipolytic dose effect-curve obtained with RP 55462, 
compared with that of different lipolytic agents (fig. 1) revealed 
that the maximal effect as well as the sensitivity of RP 55462 
were quite equivalent to those of the alkylated xanthins (IBMX, 
theophylline and caffeine). Under our working conditions, when 
rat fat cells were incubated in a buffer without ADA to remove 
adenosine released in the incubation buffer, the lipolytic action 
of the alkylated xanthins is attributable to the inhibition of 
CAMP-PDE activity and to the blockade of the inhibitory A1 - 
adenosine receptor. Because RP 55462 behaved like the xan- 
thins in terms of efficiency, a possible action on both mecha- 
nisms was explored. Competition binding studies with ['HIPIA, 
an agonist specific for the Al-adenosine receptor on fat cell 
membranes (fig. 3) revealed that RP 55462 was unable to 
interact with this receptor unlike IBMX or theophylline. 
In fact, RP 55462 inhibited, in a dose-dependent manner, 
the CAMP-PDE activity of rat adipose tissue as found with 
IBMX, theophylline and caffeine (fig. 4). The CAMP-PDE 
activity measured corresponds to the total population of CAMP- 
PDE contained in the rat adipose tissue, without discrimination 
of the different isoforms. From our results, we cannot conclude 
to a specific inhibition of the low K, CAMP-PDE or the 
particulate CAMP-PDE (endoplasmic reticulum-associated) 
implicated in the regulation of lipolysis and specifically inhib- 
ited by cilostamide (Elks et d, 1985, Degerman et al., 1987). 
The good correlation existing between the lipolytic activity and 
the capacity of IBMX, RP 55462, theophylline and caffeine to 
inhibit the CAMP-PDE activity (table 3) allowed us to conclude 
that the lipolytic activity of RP 55462 was certainly mediated 
by the inhibition of CAMP-PDE activity of the fat cell. This 
action easily explains the enhancement of the isoproterenol- or 
synacthen-induced lipolysis (through limitation of CAMP deg- 
radation) reported previously (Saulnier-Blache et d ,  1989). 
The connection between the lipolytic action and the inhibition 
of CAMP-PDE activity is also confirmed by the comparative 
study performed with various piperazinopyrimidine derivatives 
(table 3). The agents exerting a lipolytic effect also inhibited 
CAMP-PDE activity whereas those inactive on lipolysis did not 
affect noticeably the activity of CAMP-PDE. 
In conclusion of the in vitm studies, a double potency of RP 
55462 was revealed: this agent is an alpha-2-antagonist (Saul- 
nier Blache et al., 1989) and an inhibitor of CAMP-PDE activ- 
ity. 
In as much as some alpha-2-antagonists, when administered 
in vivo, promote lipid-mobilization (Galitzky et al., 1988, Taouis 
et d ,  1988), a comparison of the lipid mobilizing actions of 
yohimbine and RP 55462 was performed in alert dogs. A 
lipomobilizing effect of yohimbine (alpha-2 adrenergic antago- 
nist) was demonstrated previously in dogs and in human sub- 
jecta, it was abolished completely by pretreatment with pro- 
pranolol. These results suggest that the major effect of yohim- 
bine is to increase the sympathetic tone in dogs (Taouis et d ,  
1988). The activation of the lipolysis is promoted by the release 
of norepinephrine and can be blocked by a pretreatment with 
propranolol. 
We showed previously a lipid mobilizing effect of RP 55462 
(Saulnier-Blache et al., 1989). So, it was interesting to know if 
the inhibitory effect of RP 55462 on CAMP-PDE, revealed in 
vitro, can be implicated in its lipomobilizing action and can 
even be dissociated from its alpha-2-antagonist-dependent li- 
pomobilizing effect. 
Pretreatment of alert dogs with propranolol only suppressed 
the faster component in the lipid mobilizing effect of RP 55462 
(15 and 30 min) without affecting the slower one (at 45 rnin). 
On the contrary the lipomobilizing effect of yohimbine was 
abolished completely (fig. 5) by propranolol pretreatment. 
These experiments revealed the existence of an alpha-2 adre- 
nergic antagonist component in the lipomobilizing action of 
the RP 55462 which can be blocked by propranolol. This initial 
effect is followed by another which takes place more slowly and 
which cannot be blocked by propranolol. The late onset lipo- 
mobilizing effect of RP 55462 can probably be attributable to 
i t .  CAMP-PDE inhibitory action. Infusion of theophylline (a 
CAMP-PDE inhibitor without alpha-2 adrenergic antagonist 
activity) in dogs, promoted, with a slow onset (45 min) an 
increase of plasma NEFA levels which cannot be blocked by 
propranolol (data no shown). Such an action is evoking a 
similarity with the effects described for RP 55462. 
The in vivo studies suggested that the lipomobilizing effect 
of RP 55462, is a combination between an indirect alpha-2- 
blocking action which is abolished by propranolol and a direct 
lipolytic action due to the inhibition of CAMP-PDE which is 
without propranolol 
+ propranolol lmglkg 
1 5  30 45 rnin 15 30 60 rnin 
RP 55462 lmglkg Yohimbine O.Srng/kg 
Fig. 5. Influence of propranold administration on the lipid mobilizing 
effect of RP 55462 and yohimbine in dogs. Alert dogs were treated (s) 
or not (0) with 1 mgFg of propranold (bolus i.v.) 30 rnin before injection 
of 1 mghg of RP 55462 (A) or 0.5 mg/kg of yohimbine (B) (bolus i.v.). 
Blood samples were collected before injection and 15, 30, 45 and 60 
rnin after RP 55462 or yohimbine injection. Plasma NEFA levels were 
determined as described under 'Materials and Methods." Results are 
expressed as the d i i  between NEFA levels at time 0 and NEFA 
levels at time 15, 30, 45 and 60 min. Each point represents the mean f 
S.E. of four separate experiments. 
resistant to propranolol treatment. To conclude, the piperazin- 
opyrimidine derivative RP 55462 appears to be an original tool 
possessing a lipid mobilizing activity originating from at least 
two mechanisms of action. It could also be an experimental 
tool for in vitm studies when CAMP-PDE inhibition is required 
without any action on Al-adenosine receptor sites in lipolysis 
studies or adenylate cyclase assays. 
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